Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 28, 2026

Quantification of Hypopigmentation Activity In Vitro
06:08

Quantification of Hypopigmentation Activity In Vitro

Published on: March 6, 2019

Management of Facial Immune Checkpoint Inhibitor-Induced Vitiligo with Topical Ruxolitinib: Quantitative Assessment

Thomas Breakell1,2,3, Paolo Neri4, Léonie A N Staats1,2,3

  • 1Department of Dermatology, Uniklinikum Erlangen, Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.

Current Oncology (Toronto, Ont.)
|May 26, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

S1 guideline sweat gland carcinoma.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

[63/m with a painful mass on the forehead following kidney transplantation : Preparation for the medical specialist examination: part 61].

Dermatologie (Heidelberg, Germany)·2026
Same author

Organ Involvement and Treatment Response across Cutaneous Sarcoidosis Subtypes.

Acta dermato-venereologica·2026
Same author

Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells.

Nature communications·2026
Same author

Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study.

International journal of dermatology·2026
Same author

[Immune checkpoint inhibitor-induced bullous pemphigoid].

Dermatologie (Heidelberg, Germany)·2026

Topical ruxolitinib cream effectively treated facial vitiligo in three patients after immune checkpoint inhibitor therapy. Significant repigmentation and improved quality of life were observed with no side effects.

Area of Science:

  • Dermatology
  • Oncology
  • Immunology

Background:

  • Immune checkpoint inhibitors (ICIs) improve advanced melanoma outcomes but cause immune-related adverse events (irAEs).
  • Vitiligo is a common irAE associated with better patient survival but causes significant cosmetic concerns, especially on the face.
  • Existing treatments for vitiligo are often insufficient.

Purpose of the Study:

  • To explore the efficacy of topical ruxolitinib in treating facial vitiligo induced by ICI therapy.
  • To assess the impact of ruxolitinib on repigmentation and quality of life in these patients.

Main Methods:

  • An exploratory analysis involving three patients with facial vitiligo post-ICI therapy.
  • Application of 1.5% ruxolitinib cream twice daily to facial areas.
Keywords:
JAK inhibitorimmune checkpoint inhibitorimmune-related adverse eventmelanomaruxolitinibvitiligo

More Related Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Related Experiment Videos

Last Updated: May 28, 2026

Quantification of Hypopigmentation Activity In Vitro
06:08

Quantification of Hypopigmentation Activity In Vitro

Published on: March 6, 2019

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

  • Quantification of repigmentation using a semi-automatic tool and assessment of quality of life via questionnaires.

    • Main Results:

    • Extensive facial repigmentation observed after 6-12 months, with percentages of 95.7%, 78.9%, and 99.1%.
    • Significant reductions in disease burden reported: 57.6% decrease in Vitiligo DLQI and 68.2% in Vitiligo-specific Quality of Life.
    • Treatment was well-tolerated with no observed side effects.

    Conclusions:

    • Topical ruxolitinib demonstrates promising efficacy for facial vitiligo in patients treated with ICIs.
    • Ruxolitinib offers a potential new treatment option, improving both cosmetic appearance and quality of life.
    • Further large-scale, prospective studies are needed to confirm these findings and assess long-term safety.